E Jabbour

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. doi request reprint Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis
    Elias Jabbour
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX Electronic address
    Clin Lymphoma Myeloma Leuk 14:93-7. 2014
  2. doi request reprint Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies
    Elias Jabbour
    Haematologica 99:7-18. 2014
  3. doi request reprint Clofarabine in the treatment of myelodysplastic syndromes
    Jeffrey Bryan
    The University of Texas, M D Anderson Cancer Center, Department of Leukemia, 1515 Holcombe Blvd Box 428 Houston, TX 77030, USA 1 713 792 4764 1 713 794 4297
    Expert Opin Investig Drugs 23:255-63. 2014
  4. doi request reprint Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia
    Elias Jabbour
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX Electronic address
    Semin Hematol 50:271-83. 2013
  5. doi request reprint A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase
    Elias Jabbour
    The University of Texas, MD Anderson Cancer Center, Houston, TX Electronic address
    Clin Lymphoma Myeloma Leuk 13:646-56. 2013
  6. doi request reprint Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options
    Elias J Jabbour
    The University of Texas, MD Anderson Cancer Center, Houston, TX Electronic address
    Clin Lymphoma Myeloma Leuk 13:515-29. 2013
  7. doi request reprint Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine
    Elias Jabbour
    The University of Texas MD Anderson Cancer Center, Houston, TX Electronic address
    Clin Lymphoma Myeloma Leuk 13:592-6. 2013
  8. doi request reprint The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure
    Elias Jabbour
    Department of Leukemia, MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA
    Clin Lymphoma Myeloma Leuk 13:302-6. 2013
  9. doi request reprint Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance
    E Jabbour
    Department of Leukemia, MD Anderson Cancer Center, The University of Texas, Houston, TX 77030, USA
    Leukemia 27:907-13. 2013
  10. doi request reprint Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine
    Elias Jabbour
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma Myeloma Leuk 13:131-8. 2013

Detail Information

Publications97

  1. doi request reprint Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis
    Elias Jabbour
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX Electronic address
    Clin Lymphoma Myeloma Leuk 14:93-7. 2014
    ..Thus, the outcome of AML evolving from MDS after hypomethylating agent failure is poor and not improved with HDAC. Novel therapies directed toward this emerging entity are urgently needed. ..
  2. doi request reprint Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies
    Elias Jabbour
    Haematologica 99:7-18. 2014
    ..This article reviews the role of phosphoinositide 3-kinase signaling in hematologic malignancies and the potential clinical utility of inhibitors that target this pathway. ..
  3. doi request reprint Clofarabine in the treatment of myelodysplastic syndromes
    Jeffrey Bryan
    The University of Texas, M D Anderson Cancer Center, Department of Leukemia, 1515 Holcombe Blvd Box 428 Houston, TX 77030, USA 1 713 792 4764 1 713 794 4297
    Expert Opin Investig Drugs 23:255-63. 2014
    ....
  4. doi request reprint Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia
    Elias Jabbour
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX Electronic address
    Semin Hematol 50:271-83. 2013
    ..In this review, we will highlight the results of recent clinical trials in which outcomes of CML and AML have been influenced significantly. Also, novel approaches to sequencing and combining available therapies will be covered...
  5. doi request reprint A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase
    Elias Jabbour
    The University of Texas, MD Anderson Cancer Center, Houston, TX Electronic address
    Clin Lymphoma Myeloma Leuk 13:646-56. 2013
    ..Three BCR-ABL inhibitors, imatinib, nilotinib, and dasatinib, have been approved by the US Food and Drug Administration for first-line treatment of patients with newly diagnosed CML in chronic phase (CML-CP)...
  6. doi request reprint Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options
    Elias J Jabbour
    The University of Texas, MD Anderson Cancer Center, Houston, TX Electronic address
    Clin Lymphoma Myeloma Leuk 13:515-29. 2013
    ..This review summarizes the molecular mechanisms and clinical consequences of TKI resistance and addresses the current and future treatment approaches for patients with TKI-resistant CML. ..
  7. doi request reprint Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine
    Elias Jabbour
    The University of Texas MD Anderson Cancer Center, Houston, TX Electronic address
    Clin Lymphoma Myeloma Leuk 13:592-6. 2013
    ..This retrospective analysis evaluated response to decitabine using updated IWG criteria in patients pooled from 2 decitabine trials...
  8. doi request reprint The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure
    Elias Jabbour
    Department of Leukemia, MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA
    Clin Lymphoma Myeloma Leuk 13:302-6. 2013
    ....
  9. doi request reprint Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance
    E Jabbour
    Department of Leukemia, MD Anderson Cancer Center, The University of Texas, Houston, TX 77030, USA
    Leukemia 27:907-13. 2013
    ..Even in the presence of poor disease characteristics, nilotinib provided significant clinical benefit in patients with imatinib-resistant or -intolerant CML. This system may yield insight on the prognosis of patients...
  10. doi request reprint Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine
    Elias Jabbour
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma Myeloma Leuk 13:131-8. 2013
    ..Identifying potential prognostic factors for survival may guide decitabine treatment decisions and improve outcomes...
  11. doi request reprint Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study
    Elias Jabbour
    Department of Stem Cell Transplantation, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Am J Hematol 88:198-200. 2013
    ..001). These results would suggest that prospective studies are needed to delineate the timing and efficacy of allo-SCT in the HMA era...
  12. doi request reprint Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management
    Elias Jabbour
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Am J Hematol 87:1037-45. 2012
    ..Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm with an incidence of one-two cases per 100,000 adults and accounts for ∼15% of newly diagnosed cases of leukemia in adults...
  13. doi request reprint Adherence to BCR-ABL inhibitors: issues for CML therapy
    Elias Jabbour
    The University of Texas M D Anderson Cancer Center, Department of Leukemia, Unit 428, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Clin Lymphoma Myeloma Leuk 12:223-9. 2012
    ..To maximize adherence, CML treatment should be individualized to the patient and simplified as appropriate...
  14. pmc Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia
    Elias Jabbour
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma Myeloma Leuk 12:244-51. 2012
    ..The overall 4-week mortality rate was 9%. In conclusion, BIDFA is active and safe in heavily pretreated patients with myeloid malignancies...
  15. pmc EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience
    Elias Jabbour
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 119:4524-6. 2012
    ..In conclusion, 8% of patients with chronic phase chronic myeloid leukemia treated at our institution are in the high EUTOS score; in this population, the EUTOS score was not predictive for outcome...
  16. doi request reprint Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia
    Elias J Jabbour
    Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA
    Am J Hematol 87:687-91. 2012
    ..Controlling risk factors for poor adherence in combination with patient education that includes direct communication between the health care team and the patient are essential components for maximizing the benefits of TKI therapy...
  17. doi request reprint Tyrosine kinase inhibitors in acute and chronic leukemias
    Maro Ohanian
    The University of Texas, M D Anderson Cancer Center, Department of Leukemia, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA
    Expert Opin Pharmacother 13:927-38. 2012
    ..Targeted therapy with TKIs has continued to be an area of active research and development in the care of acute and chronic leukemia patients...
  18. doi request reprint Chronic myeloid leukemia: mechanisms of resistance and treatment
    Elias Jabbour
    The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Hematol Oncol Clin North Am 25:981-95, v. 2011
    ..This article guides the treating physician with a rational approach in the management of patients with chronic myeloid leukemia who fail initial treatment with imatinib or lose response while on therapy with imatinib...
  19. pmc Suboptimal responses in chronic myeloid leukemia: implications and management strategies
    Elias Jabbour
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:1181-91. 2012
    ..Identification of suboptimal responders or patients failing treatment using hematologic, cytogenetic, and molecular techniques allows physicians to alter therapy earlier in the treatment course to improve long-term outcomes...
  20. ncbi request reprint Targeted therapy in chronic myeloid leukemia
    Elias Jabbour
    The University of Texas MD Anderson Cancer Center, Department of Leukemia, Unit 428, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Expert Rev Anticancer Ther 8:99-110. 2008
    ..Future CML treatment may involve combination strategies. Overall, targeted agents have significantly improved the prognosis of patients diagnosed with CML...
  21. doi request reprint Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
    E Jabbour
    Leukemia Department, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Leukemia 25:201-10. 2011
    ..We also describe how common side effects can be effectively managed and offer a working definition of intolerance that may be useful to clinicians when they consider switching between TKIs...
  22. ncbi request reprint Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias
    Elias Jabbour
    The University of Texas, MD Anderson Cancer Center, Department of Leukemia, Unit 428, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Expert Opin Investig Drugs 17:1127-36. 2008
    ..Preclinical and clinical investigations demonstrate that nilotinib effectively overcomes imatinib resistance, and has induced high rates of hematologic and cytogenetic responses in CML post imatinib failure...
  23. doi request reprint Optimizing treatment with Bcr-Abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: focus on dosing schedules
    Elias Jabbour
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma Myeloma 8:S75-81. 2008
    ..As experience with these agents continues to mature, we might optimize the treatment efficacy and safety profiles by altering dose regimens...
  24. doi request reprint Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies
    Elias Jabbour
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 112:2341-51. 2008
    ..Combination therapies that augment the epigenetic effect of decitabine will likely improve responses and extend its use for the treatment of other malignancies...
  25. pmc Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?
    Elias Jabbour
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston, 77030, USA
    Mayo Clin Proc 84:161-9. 2009
    ..Patient and disease characteristics should be carefully considered to optimize treatment strategy for CML...
  26. doi request reprint Clinical algorithms for the treatment of patients with chronic myeloid leukemia: the 2010 perspective
    Elias Jabbour
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Clin Lymphoma Myeloma Leuk 10:S6-13. 2010
    ..To optimize therapeutic benefit, clinicians should select treatment based on each patient's historical response, adverse event tolerance level, and risk factors...
  27. doi request reprint Advances in the biology and therapy of patients with chronic myeloid leukaemia
    Elias Jabbour
    Department of Leukemia, The University of Texas, Unit 428, M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Best Pract Res Clin Haematol 22:395-407. 2009
    ..Herein, we review some of these targeted therapies, particularly those for which clinical data are already available...
  28. doi request reprint Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history
    E Jabbour
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 423, Houston, TX 77030, USA
    Leukemia 24:6-12. 2010
    ..Here, we propose a treatment algorithm for imatinib-resistant patients based on BCR-ABL mutation status and patient history...
  29. doi request reprint Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure
    Elias Jabbour
    Department of Leukemia, M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma Myeloma 9:S272-9. 2009
    ..Successful treatment of patients with disease harboring T315I might lie in the effective combination or sequencing of these new agents with existing TKI therapies...
  30. ncbi request reprint Understanding the role of mutations in therapeutic decision making for chronic myeloid leukemia
    Elias Jabbour
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    Semin Hematol 46:S22-6. 2009
    ..The choice of therapy should be guided by multiple factors, including mutational analysis, disease phase, patient characteristics, and the safety profile of the agents...
  31. doi request reprint Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy
    Elias Jabbour
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:3830-4. 2010
    ..The prognosis of patients with myelodysplastic syndrome (MDS) after decitabine failure is not known...
  32. doi request reprint Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy
    Elias Jabbour
    Department of Leukemia, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Oncologist 14:489-96. 2009
    ....
  33. doi request reprint Treatment selection after imatinib resistance in chronic myeloid leukemia
    Elias Jabbour
    Department of Leukemia, MD Anderson Cancer Center, Houston, TX 77030, USA
    Target Oncol 4:3-10. 2009
    ..The disease and patient characteristics at the time of imatinib failure should be evaluated before choosing second-line therapy to optimize the therapeutic benefit without unnecessary delay...
  34. doi request reprint Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?
    Elias Jabbour
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Hematol 47:344-53. 2010
    ..To optimize therapeutic benefit, clinicians should select treatment based on each patient's historical response, adverse-event tolerance level, and risk factors...
  35. doi request reprint Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure
    Elias Jabbour
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 117:1822-7. 2011
    ..This scoring system could serve to advise patients of their prognosis and treatment options, as well as to evaluate the benefit of newer alternate options...
  36. doi request reprint Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia
    Elias Jabbour
    Leukemia Department, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 117:1800-11. 2011
    ..Clinical trial data from an evaluation of the response of specific mutant BCR-ABL clones to TKIs is needed to establish the role of mutation testing in the management of CML...
  37. doi request reprint Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications
    Elias Jabbour
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 112:2112-8. 2008
    ..Although molecular monitoring has a clear role in assessing residual disease and determining the risk of disease progression in patients with CML, the importance of cytogenetic monitoring should not be ignored...
  38. pmc The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors
    Elias Jabbour
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Blood 118:4541-6; quiz 4759. 2011
    ..The achievement of early CCyR remains a major determinant of chronic myeloid leukemia outcome regardless of whether MMR is achieved or not...
  39. pmc Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?
    Elias Jabbour
    University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA
    J Clin Oncol 29:4260-5. 2011
    ..It is unknown whether these definitions apply to patients treated with second-generation tyrosine kinase inhibitors (TKIs)...
  40. doi request reprint Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors
    Elias Jabbour
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 117:897-906. 2011
    ..To optimize therapeutic benefit, clinicians should select treatment based on each patient's historic response, adverse-event tolerance, and risk factors...
  41. ncbi request reprint Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure
    Elias Jabbour
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 108:1421-3. 2006
    ..Seven patients are alive (6 in CMR) for a median of 19 months. Allo-SCT remains an important salvage option for patients who develop resistance to imatinib through Bcr-Abl mutations...
  42. doi request reprint Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations
    Elias Jabbour
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 114:2037-43. 2009
    ..Mutation scoring can predict outcome in CML-chronic phase with imatinib failure treated with second-generation TKIs and can help in therapy selection. More complex prognostic models will be required for advanced stages of disease...
  43. ncbi request reprint Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate
    E Jabbour
    Department of Leukemia, The University of Texas, UT MD Anderson Cancer Center, Houston, TX 77030, USA
    Leukemia 20:1767-73. 2006
    ..In conclusion, P-loop mutations were not associated with poor outcome, suggesting that the prognosis of patients who fail imatinib is multifactorial...
  44. ncbi request reprint Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome
    M De Lima
    Department of Stem Cell Transplantation and Cell Therapy, U T M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Leukemia 22:258-64. 2008
    ..Median follow-up was 37 months. Median event-free and overall survival was 6 and 11 months. GO 2 mg m(-2) can be safely added to fludarabine/melphalan, and this regimen merits further evaluation...
  45. ncbi request reprint Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs?
    Elias Jabbour
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Oncology (Williston Park) 21:653-62; discussion 663-4, 667-8. 2007
    ..Combination strategies are currently being investigated in preliminary clinical studies and may prove to be useful. Overall, there are an increasing number of treatment options now available for patients with CML...
  46. ncbi request reprint Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate
    Elias Jabbour
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 107:480-2. 2006
    ..SBT is still a rare event, probably less common than that observed with IFN-alpha therapy. Continuous monitoring of patients treated with imatinib is mandatory...
  47. ncbi request reprint Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias
    Elias Jabbour
    The University of Texas MD Anderson Cancer Center, Department of Leukaemia, Box 428, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Expert Opin Investig Drugs 16:679-87. 2007
    ..Dasatinib was recently approved by the FDA for use in Philadelphia-positive leukaemias in patients who are resistant or intolerant to imatinib...
  48. ncbi request reprint Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia
    Elias Jabbour
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Blood 109:3214-8. 2007
    ..Liposomal cytarabine given via intrathecal route concomitantly with systemic chemotherapy that crosses the blood-brain barrier such as high-dose MTX and cytarabine can result in significant neurotoxicity...
  49. doi request reprint Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase
    Carmen Fava
    Department of Leukemia, M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 113:5058-63. 2009
    ..These results suggest that achievement of a MCyR without concomitant CHR is associated with poor outcome...
  50. doi request reprint Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia
    Elias Jabbour
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 115:1899-905. 2009
    ..The authors hypothesized that low doses of the hypomethylating agent 5-azacitidine may maximize the graft-versus-leukemia effect and may be tolerated well after allogeneic transplantation (HSCT)...
  51. doi request reprint Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation
    Y Chen
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Leukemia 27:836-42. 2013
    ..001) and relapse-free survival (P<0.001) in patients with AML and 11q23 abnormalities...
  52. ncbi request reprint New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance
    Elias Jabbour
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Hematol 44:S25-31. 2007
    ..Herein, we review some of these strategies, particularly those for which clinical data are currently available...
  53. doi request reprint Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy
    Elias Jabbour
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 112:53-5. 2008
    ..Although the T315I mutation is resistant to currently available TKIs, survival of patients with T315I remains mostly dependent on the stage of the disease, with many CP patients having an indolent course...
  54. ncbi request reprint Clinical experience with decitabine in North American patients with myelodysplastic syndrome
    Karen W L Yee
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Ann Hematol 84:18-24. 2005
    ....
  55. doi request reprint Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors
    Elias Jabbour
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, USA
    Blood 112:4839-42. 2008
    ..45). Patients in CP had better outcome, with a 2-year survival of 75%. F317L mutation is resistant to dasatinib but sensitive to other TKIs. The prognosis is dependent mostly on the disease stage...
  56. doi request reprint Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen
    Deborah Thomas
    Department of Leukemia, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:4580-9. 2010
    ..5 g/m2 IV on Days 1 and 2) to the standard hyper-CVAD regimen (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high dose methotrexate and cytarabine) would improve outcome...
  57. doi request reprint Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:5568-74. 2010
    ..The objectives of this study were to define the prognosis for adult patients with ALL after first salvage through multivariate analyses of patient and disease characteristics...
  58. pmc Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays
    C Cameron Yin
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer Sci 101:2005-10. 2010
    ..Rapid reselection of TKI-resistant clones occurs following therapy switch in CML...
  59. doi request reprint Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia
    Hagop Kantarjian
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Blood 116:4422-9. 2010
    ..In summary, the prognosis of most patients (72%) ≥ 70 years of age with AML is poor with intensive chemotherapy (8-week mortality ≥ 30%; median survival < 6 months)...
  60. doi request reprint Current and future management options for myelodysplastic syndromes
    Jeffrey Bryan
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Drugs 70:1381-94. 2010
    ..This review focuses on supportive care modalities, the approved agents indicated for the treatment of MDS and future directions for the treatment of MDS, including agents under clinical investigation...
  61. doi request reprint Emerging therapy for the treatment of acute lymphoblastic leukemia
    Amber Fullmer
    The University of Texas, MD Anderson Cancer Center, Department of Leukemia, 1515 Holcombe Blvd Box 428 Houston, TX 77030, USA
    Expert Opin Emerg Drugs 15:1-11. 2010
    ....
  62. pmc Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase
    Jorge E Cortes
    Departments of Leukemia and Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 28:392-7. 2010
    ..Although most patients with chronic myeloid leukemia (CML) in chronic phase respond well to front-line therapy with imatinib, some patients do not achieve the desirable end point, and others may eventually lose response or are intolerant...
  63. pmc Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia
    Guillermo Garcia-Manero
    Department of Leukemia, Box 428, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 108:3271-9. 2006
    ..In summary, this combination of epigenetic therapy in leukemia was safe and active, and was associated with transient reversal of aberrant epigenetic marks...
  64. ncbi request reprint Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:265-73. 2007
    ..In this study, the authors update their experience with decitabine in patients with MDS and analyze the cytogenetic response patterns and prognostic factors associated with decitabine therapy...
  65. ncbi request reprint Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges
    Elias Jabbour
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Clin Lymphoma Myeloma 7:S51-7. 2007
    ..The outlook today for patients with CML is much brighter than that of a few years ago...
  66. ncbi request reprint Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome
    Hagop Kantarjian
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:1090-8. 2006
    ....
  67. ncbi request reprint Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia
    Francis Giles
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Clin Cancer Res 11:7817-24. 2005
    ..A phase I study of cloretazine combined with cytarabine (1-beta-d-arabinofuranosylcytosine, ara-C) was conducted in patients with refractory disease...
  68. ncbi request reprint Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib
    Jorge Cortes
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:1295-302. 2007
    ..Lonafarnib can inhibit the proliferation of imatinib-resistant cells and increases imatinib-induced apoptosis in vitro in cells from imatinib-resistant patients...
  69. ncbi request reprint Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase
    Elias Jabbour
    Department of Leukemia and, University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 110:2991-5. 2007
    ..CAs occur in Ph-negative cells in a small percentage of patients with newly diagnosed CML treated with IM. In rare instances, these could reflect the emergence of a new malignant clone...
  70. ncbi request reprint Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond
    Elias Jabbour
    Department of Leukemia, Unit 428, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    IDrugs 10:468-79. 2007
    ..Nilotinib is undergoing clinical trials in patients with newly diagnosed CML, acute lymphoblastic leukemia and gastrointestinal stromal tumors, among other indications...
  71. ncbi request reprint Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors
    Jorge Cortes
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston, 77030, USA
    Blood 110:4005-11. 2007
    ..In this study, there was no marked increase in development of T315I...
  72. ncbi request reprint Introduction: chronic myelogenous leukemia (CML)
    Elias Jabbour
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Semin Hematol 44:S1-3. 2007
  73. doi request reprint Standard management of patients with chronic myeloid leukemia
    Carmen Fava
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Clin Lymphoma Myeloma 9:S382-90. 2009
    ..Herein, we review some of these targeted therapies, particularly those for which clinical data are already available...
  74. doi request reprint Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors
    Dan Jones
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:985-94. 2008
    ..Patterns of KD mutations in Philadelphia chromosome (Ph)-positive acute lympho- blastic leukemia (ALL) are less well studied...
  75. doi request reprint Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis
    Gabriela Rondon
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 14:859-66. 2008
    ..Collection of autologous stem cells prior to high-risk allografting can salvage a fraction of patients and lead to prolonged survivals...
  76. doi request reprint Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy
    Elias Jabbour
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 113:2154-60. 2009
    ..In conclusion, imatinib dose escalation can induce sustained responses in a subset of patients with cytogenetic failure and a previous cytogenetic response to standard-dose imatinib...
  77. doi request reprint Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era
    Richard Champlin
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma Myeloma 9:S261-5. 2009
    ..This approach, including posttransplantation treatment with TKIs and donor lymphocyte infusion, produces a high fraction of durable molecular complete remissions...
  78. pmc Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    J Clin Oncol 27:3659-63. 2009
    ..The clinical significance of increasing levels of QPCR in patients in CGCR is uncertain...
  79. pmc Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia
    Jorge E Cortes
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 28:398-404. 2010
    ..Dasatinib is effective therapy for chronic myeloid leukemia (CML) after imatinib failure. In this study, we investigate the efficacy of dasatinib as initial therapy for patients with CML in early chronic phase...
  80. ncbi request reprint Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation
    E Jabbour
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Bone Marrow Transplant 40:431-5. 2007
    ..Overall, we found that fludarabine and ATG conditioning before a second SCT allows engraftment of donor hematopoiesis. Future studies should include more intense GVHD prophylaxis...
  81. ncbi request reprint Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse
    Francis Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, 77230 1402, USA
    Br J Haematol 134:58-60. 2006
    ..The EPI is reproducible and useful...
  82. ncbi request reprint Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986
    Rashid Saba
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 103:2551-7. 2005
    ..In 1986, a Phase II trial of recombinant interferon-alpha (IFN-alpha) was initiated as therapy for patients with essential thrombocythemia (ET)...
  83. ncbi request reprint Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center
    Yasuhiro Oki
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 107:880-4. 2006
    ..51, P = .049). These results confirm the poor prognosis of M7 AML and indicate that other biologic characteristics beyond cytogenetic abnormalities likely play a role in this disease...
  84. ncbi request reprint 2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome
    Elias Jabbour
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer 104:541-6. 2005
    ..Hypereosinophilic syndrome (HES) is a rare, disabling, and incurable disease. In this study, a combination of 2-chlorodeoxyadenosine (2-CdA) and cytosine arabinoside (ara-C) chemotherapy was evaluated in patients with HES...
  85. ncbi request reprint Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma
    Elias Jabbour
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:2481-9. 2007
    ....
  86. ncbi request reprint Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity
    Elias Jabbour
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:340-4. 2007
    ..It is unknown whether the use of these NTKIs before HSCT increases transplant-related toxicity...
  87. pmc Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia
    Hui Yang
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 113:1892-8. 2009
    ..68, P= .003) and overall survival (hazard ratio=2.69, P= .002). In conclusion, detection of epigenetic alterations allows the identification of patients with ALL with standard risk but with poor prognosis...
  88. ncbi request reprint Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment
    Elias Jabbour
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer J 13:357-65. 2007
    ..Efforts to optimize therapy in CML have resulted in new and revised treatment guidelines or algorithms, which are reviewed here...
  89. ncbi request reprint Current and emerging treatment options in chronic myeloid leukemia
    Elias Jabbour
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:2171-81. 2007
    ..Stem cell transplantation remains a useful option, although it is not generally used as first-line treatment. Overall, there are an increasing number of treatment options available for patients with CML...
  90. doi request reprint Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes
    Elias Jabbour
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 112:1089-95. 2008
    ..Approximately 15,000 new cases of myelodysplastic syndromes (MDS) are expected in the United States each year...
  91. ncbi request reprint Stem cell transplantation for chronic lymphocytic leukemia: should not more patients get a transplant?
    E Jabbour
    Department of Blood and Bone Marrow Transplant, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Bone Marrow Transplant 34:289-97. 2004
    ..Randomized trials designed according to the new biologic prognostic parameters described in chronic lymphocytic leukemia are required to better define the role of NMA SCT in the near future...
  92. ncbi request reprint Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action
    Elias Jabbour
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 45:2187-95. 2004
    ..Ongoing studies will better determine their mechanism of action and the role of combination with other agents, defining their place in the therapeutic arsenal of hematologic disorders...
  93. ncbi request reprint Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia
    Alfonso Quintas-Cardama
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 107:1525-9. 2006
    ..9-Nitro-camptothecin (9-NC) is a new oral topoisomerase inhibitor with a good safety profile. The aims of the current study were to evaluate the activity and safety of 9-NC in MDS and CMML...
  94. ncbi request reprint PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study
    Elias Jabbour
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:2012-8. 2007
    ..PEG-IFN-alpha-2b is a pegylated IFN-alpha-2b with a significant advantage over nonpegylated form in that it is administered once a week...
  95. ncbi request reprint Novel tyrosine kinase inhibitors in chronic myelogenous leukemia
    Elias Jabbour
    Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA
    Curr Opin Oncol 18:578-83. 2006
    ..The successful introduction of the tyrosine kinase inhibitors has initiated a new era in the management of chronic myeloid leukemia...
  96. ncbi request reprint Dasatinib
    Hagop Kantarjian
    Nat Rev Drug Discov 5:717-8. 2006
  97. ncbi request reprint Clinical activity of tipifarnib in hematologic malignancies
    Elias Jabbour
    MD Anderson Cancer Center, Department of Leukemia, Unit 428, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Expert Opin Investig Drugs 16:381-92. 2007
    ..Ongoing studies will better determine the mechanism of action of tipifarnib and the role of combination with other agents, defining its place in the therapeutic arsenal of hematologic disorders...